Abstract
In drug discovery, metabolite identification data is used to identify metabolic soft spots in research molecules to facilitate reduced metabolism in subsequently designed compounds. In addition, knowledge about exact metabolite structures enables the assessment of risks associated with active, reactive, or toxic metabolites. In the present work, we exemplify how metabolite identification data is generated and utilized at AstraZeneca. We share metabolite transformation scheme data derived from incubations in human hepatocytes for a set of 120 compounds. Comparison with other in-house generated metabolite identification data, both in terms of chemical space analysis and in vitro properties, is performed, including the characterization of observed metabolic pathways. For selected compounds, the correlation between in vitro and in vivo metabolite data in animal species is provided. Finally, usage of shared metabolite identification data for drug metabolism prediction using machine learning and artificial intelligence approaches is discussed.
Supplementary weblinks
Title
AstraZeneca metabolite identification (MetID) schemes for 120 compounds
Description
This file contains metabolite identification schemes for 120 compounds, derived from incubations in human hepatocytes (Gender: Pooled, Hepatocyte Concentration: 1 million cells/mL, Compound Concentration: 4 µM, Incubation Time: 120 min).
Actions
View